INVA
Innoviva, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.28
−0.33%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 443.4M | 425.1M | 358.7M | 310.5M | 331.3M |
| Cost of Revenue | 119.3M | 117.6M | 36.6M | 42.6M | 13.8M |
| Gross Profit | 324.1M | 307.5M | 322.1M | 267.8M | 317.5M |
| Operating Expenses | |||||
| R&D Expense | 28.7M | 30.6M | 13.7M | 33.9M | 41.4M |
| SG&A Expense | 126.5M | 113.2M | 115.7M | 98.2M | 63.5M |
| General & Admin Expense | 34.6M | — | — | — | 63.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 6.4M | — | 25.9M | 21.8M | 5.6M |
| Total Operating Expenses | 161.5M | 143.8M | 155.2M | 153.9M | 110.6M |
| Cost and Expenses | 280.9M | 261.4M | 191.8M | 196.6M | 124.3M |
| Operating Income (EBIT) | 162.6M | 163.7M | 166.9M | 113.9M | 207.0M |
| Non-Operating | |||||
| Interest Income | 30.2M | 21.1M | 19.1M | 15.8M | 6.4M |
| Interest Expense | 18.2M | 16.7M | 22.2M | 19.2M | 15.8M |
| Net Interest Income | 12.0M | 4.4M | (3.1M) | (3.3M) | (9.4M) |
| Other Non-Op Income/Expense | 256.8M | 163.1M | (129.5M) | 80.2M | 80.0M |
| Non-Operating Income (excl Interest) | (571.0M) | (179.8M) | 107.3M | (99.4M) | (95.7M) |
| EBT (Pre-Tax Income) | 419.4M | 326.9M | 37.4M | 194.1M | 286.9M |
| Income Tax Expense | 62.2M | 55.7M | 14.0M | 14.4M | 66.7M |
| Bottom Line | |||||
| Net Income | 357.2M | 271.2M | 23.4M | 179.7M | 213.9M |
| Earnings from Cont. Ops | 357.2M | 271.2M | 23.4M | 179.7M | 220.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 358.8M | 271.2M | 26.9M | 191.3M | 225.6M |
| Per Share | |||||
| Basic EPS | $4.87 | $4.02 | $0.37 | $2.92 | $3.07 |
| Diluted EPS | $4.10 | $3.30 | $0.36 | $2.20 | $2.37 |
| Revenue Per Share | $6.04 | $6.31 | $5.72 | $4.74 | $4.76 |
| Shares | |||||
| Basic Shares Outstanding | 73.4M | 67.4M | 62.7M | 65.4M | 69.6M |
| Diluted Shares Outstanding | 73.4M | 84.8M | 74.2M | 86.9M | 95.2M |
| Profitability Metrics | |||||
| EBITDA | 823.3M | 383.8M | 85.5M | 235.0M | 308.3M |
| D&A | 89.8M | 40.2M | 25.9M | 21.8M | 5.6M |
| EBIT | 733.6M | 343.6M | 59.6M | 213.3M | 302.7M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026